XML 90 R67.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and License Agreements - Additional Information (Detail) £ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Jun. 30, 2018 GBP (£) | Nov. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Nov. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Jun. 30, 2016 GBP (£) | May 31, 2016 USD ($) | Mar. 31, 2016 USD ($) | Apr. 30, 2014 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Oct. 31, 2017 USD ($) | Sep. 30, 2014 shares | Mar. 31, 2014 shares
Roche Collaboration Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development agreement, potential investment |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |
Percentage of issuance price |  |  |  |  |  |  |  |  | 90.00% |  |  |  |  |  |  |  |
Nonrefundable upfront payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |
Nonrefundable maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |
Termination fee |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |
Reductions of research and development expense |  |  |  |  |  |  |  |  |  |  |  | $ 900,000 | $ 1,500,000 |  |  |  |
MGH License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination fee |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Common units issued | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24,681
Ascenion License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination fee |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Common units issued | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,625 |
Aviragen Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones |  |  |  |  |  |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |
Cantab Related Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical and regulatory milestones |  |  |  |  | $ 5,800,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified commercial milestone | £ 5.0 |  |  |  |  | £ 5.0 |  |  |  | $ 7,000,000 | $ 6,700,000 | $ 6,200,000 |  |  |  |  |
Contract termination period |  |  |  |  | 10 years | 10 years |  |  |  |  |  |  |  |  |  |  |
Vertex License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payments |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |
Contract termination period |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones |  |  |  |  |  |  | $ 81,100,000 |  |  |  |  |  |  |  |  |  |
Contract termination period if no material development or commercialization occurs |  |  |  |  |  |  |  |  |  | 1 year | 1 year |  |  |  |  |  |
Meiji License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payments |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical and regulatory milestones |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments upon achievement of specified condition |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |
Meiji License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fee payable to counter party |  |  | 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Northern License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical, regulatory and other milestones |  |  | 7,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon closing of initial public offering |  |  | 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Northern Exchange Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon closing of initial public offering |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Northern License And Exchange Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon closing of initial public offering |  | $ 2,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Contract termination fee. + References No definition available. + Details
Name: | spro_ContractTerminationFee
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract termination period. + References No definition available. + Details
Name: | spro_ContractTerminationPeriod
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract termination period if no material development or commercialization occurs. + References No definition available. + Details
Name: | spro_ContractTerminationPeriodIfNoMaterialDevelopmentOrCommercializationOccurs
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of clinical and regulatory milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfClinicalAndRegulatoryMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of clinical regulatory and commercial milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfClinicalRegulatoryAndCommercialMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndCommercialMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified clinical, regulatory and other milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndOtherMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified commercial milestone. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedCommercialMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified pivotal condition. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementSpecifiedPivotalCondition
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License agreement milestone payments upon closing of initial public offering. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponClosingOfInitialPublicOffering
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable up front payment received. + References No definition available. + Details
Name: | spro_NonRefundableUpFrontPaymentReceived
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable maintenance fees received. + References No definition available. + Details
Name: | spro_NonrefundableMaintenanceFeesReceived
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of issuance price. + References No definition available. + Details
Name: | spro_PercentageOfIssuancePrice
Namespace Prefix: | spro_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential investment amount for research and development. + References No definition available. + Details
Name: | spro_ResearchAndDevelopmentAgreementInvestmentAmount
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development expense reduction. + References No definition available. + Details
Name: | spro_ResearchAndDevelopmentExpenseReduction
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sublicense fee payable to counterparty. + References No definition available. + Details
Name: | spro_SublicenseFeePayableToCounterparty
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of common units issued of limited liability company (LLC). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_CommonUnitIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_RocheCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_MGHLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_AscenionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_AviragenAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_CantabRelatedAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_VertexLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_MeijiLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_NorthernLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_NorthernExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_NorthernLicenseAndExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |